Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023
Cancers · 30.07.2026 · 18 (15) · 2449
DOI: 10.3390/cancers18152449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.07.2026. Verfasst von Huiwen Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The Firs…. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Jiangsu Provincial Medical Innovation Center.
Abstract (Originalsprache)
Background
Multiple myeloma (MM) is a malignant plasma cell disorder associated with substantial mortality and long-term disability. With rapid population aging in China, its disease burden may be increasing, yet comprehensive long-term assessments remain limited.
Methods
Using data from the Global Burden of Disease Study 2023, we evaluated trends in prevalence, incidence, deaths, and disability-adjusted life years (DALYs) of MM in China from 1990 to 2023. Age-standardized rates were analyzed using Joinpoint regression to estimate temporal trends.
Results
Between 1990 and 2023, prevalence, incidence, deaths, and DALYs of MM increased markedly in China, with consistent upward trends in age-standardized rates. The burden was concentrated among older adults and was higher in males than females. Decomposition analysis showed that epidemiological changes were the primary driver of increased DALYs and deaths. Forecasting analyses suggest that although age-standardized mortality and DALY rates may gradually decline, the absolute number of deaths is expected to continue rising.
Conclusions
The burden of MM in China has increased substantially over the past three decades and is projected to remain high. Strengthening early detection, risk-oriented prevention, and long-term management strategies is essential to mitigate future disease burden.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Key Laboratory of Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
ORCID-Profile: Depei Wu
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- Jiangsu Provincial Medical Innovation Center
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Liu, H., Zhou, J., Liu, H., & Wu, D. (2026). Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023. Cancers, 18(15), 2449. https://doi.org/10.3390/cancers18152449
Vancouver
Liu H, Zhou J, Liu H, Wu D. Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023. Cancers. 2026;18(15):2449. doi:10.3390/cancers18152449
BibTeX
@article{Liu2026,
author = {Liu, Huiwen and Zhou, Jiazi and Liu, Hong and Wu, Depei},
title = {Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023},
journal = {Cancers},
year = {2026},
volume = {18},
number = {15},
pages = {2449},
doi = {10.3390/cancers18152449}
}
EUVIMED